Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Aug;14 Suppl 1:127-35.
doi: 10.1111/vco.12157. Epub 2015 Sep 14.

Masitinib Monotherapy in Canine Epitheliotropic Lymphoma

Affiliations
Clinical Trial

Masitinib Monotherapy in Canine Epitheliotropic Lymphoma

N Holtermann et al. Vet Comp Oncol. .

Abstract

This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-β, seven were negative for that receptor. Five showed strong expression of PDGFR-α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.

Keywords: clinical pathology; oncology; small animal; tumour biology; tyrosine kinase.

Similar articles

See all similar articles

Cited by 4 articles

MeSH terms

Substances

LinkOut - more resources

Feedback